CX-2009
- Generic Name
- CX-2009
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 2145115-85-9
- Unique Ingredient Identifier
- RD2I59M9FC
- Background
CX-2009 is under investigation in clinical trial NCT03149549 (PROCLAIM-CX-2009: A Trial to Find Safe and Active Doses of an Investigational Drug CX-2009 for Patients With Selected Solid Tumors).
- Associated Conditions
- -
- Associated Therapies
- -
Study to Evaluate the Safety and Antitumor Activity of CX-2009 Monotherapy and in Combination With CX-072 in Advanced Breast Cancer
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2020-10-22
- Last Posted Date
- 2024-01-23
- Lead Sponsor
- CytomX Therapeutics
- Target Recruit Count
- 125
- Registration Number
- NCT04596150
- Locations
- 🇺🇸
Virginia Cancer Specialists, Fairfax, Virginia, United States
🇺🇸Los Angeles Hematology Oncology Medical, Los Angeles, California, United States
🇺🇸USC Norris Cancer Center, Los Angeles, California, United States
PROCLAIM-CX-2009: A Trial to Find Safe and Active Doses of an Investigational Drug CX-2009 for Patients With Selected Solid Tumors
Phase 1
Terminated
- Conditions
- Interventions
- First Posted Date
- 2017-05-11
- Last Posted Date
- 2024-01-05
- Lead Sponsor
- CytomX Therapeutics
- Target Recruit Count
- 99
- Registration Number
- NCT03149549
- Locations
- 🇺🇸
USC Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸Rush University Medical Center, Chicago, Illinois, United States
🇺🇸University of Chicago, Chicago, Illinois, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath